Cardiff Oncology (CRDF) Fundamental Analysis: Revenue, Earnings & Valuation

4.71 / 10

Netural

Financial evaluation shows fair fundamentals scoring 4.7/10. Advantageous factors: Revenue-MV and Cash-MV, while concerns exist in Current assets turnover ratio and Operating revenue (YoY growth rate %). Overall judgment: cautious.

Analysis Checks(6/10)

Revenue-MV

Value-4.95

Score2/3

Weight20.27%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value-13.18

Score2/3

Weight-0.97%

1M Return-0.28%

Inventory turnover ratio

Value98.02

Score3/3

Weight29.79%

1M Return6.81%

Gross profit margin (%)

Value100.00

Score2/3

Weight7.54%

1M Return1.96%

Income tax / Total profit (%)

Value19.90

Score1/3

Weight-0.84%

1M Return-0.24%

Current assets turnover ratio

Value0.01

Score0/3

Weight-3.97%

1M Return-1.16%

Operating revenue (YoY growth rate %)

Value-13.18

Score1/3

Weight-2.25%

1M Return-0.66%

Cost of sales ratio (%)

Value71.86

Score3/3

Weight13.87%

1M Return3.51%

Asset-MV

Value-0.49

Score1/3

Weight11.32%

1M Return2.68%

Cash-MV

Value0.01

Score2/3

Weight25.23%

1M Return5.85%

Is CRDF undervalued or overvalued?

CRDF scores 4.71/10 on fundamentals and holds a Fair valuation at present. Backed by its -71.49% ROE, -7732.04% net margin, -2.35 P/E ratio, 2.38 P/B ratio, and 27.37% earnings growth, these metrics solidify its Netural investment rating.